SCHEMBL31707540

SCHEMBL31707540

C=C(Cc1nc(-c2ccc(OCCCC)cn2)no1)C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 1/20 0.38
▸ ACACA Q13085 1/20 0.38
▸ NPC1 O15118 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ HCAR2 Q8TDS4 2/20 0.36
▸ CYP4F2 P78329 5/20 0.36
▸ CYP4A11 Q02928 5/20 0.36
▸ MAPT P10636 2/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ MITF O75030 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ NCOA3 Q9Y6Q9 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ HTT P42858 1/20 0.34
▸ RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23588077 0.88 ACACB (0.52) ACACBACACANPC1SMN1; SMN2MAPT
SCHEMBL27291464 0.86 NPC1 (0.41) ACACBACACANPC1SMN1; SMN2ALDH1A1
SCHEMBL27291560 0.85 GSTP1 (0.37) ACACBACACAMAPTHTT
SCHEMBL27291368 0.82 ACACB (0.39) ACACBACACANPC1SMN1; SMN2MAPT
SCHEMBL25801910 0.80 MAPT (0.41) SMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL29973428 0.78 GSTP1 (0.40) ACACBACACAMAPTTP53
SCHEMBL23578220 0.78 GSTP1 (0.40) ACACBACACAMAPTTP53
SCHEMBL23588102 0.78 SPHK1 (0.48) NPC1SMN1; SMN2ALDH1A1NPSR1MAPT
SCHEMBL23588128 0.77 MEN1 (0.38) SMN1; SMN2ALDH1A1MAPTKMT2AHTT
SCHEMBL23588271 0.77 SPHK1 (0.53) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4634167-A1 SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE Sitryx Therapeutics Limited (GB) 2025-10-22 — — EP disclosed
Send feedback